AzTrials
AzTrials

Kidney TransplantationPhase 2/3NCT00425698

Erythropoietin (EPO) and Ischemia-reperfusion After Kidney Transplantation

A Phase 2/3 study testing Recombinant erythropoietin alpha (rHuEPO alpha) in people with Kidney Transplantation, run by Hannover Medical School at 1 site in Germany.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The hematopoetic cytokine erythropoietin (EPO) has been shown to reduce programmed cell death and tissue destruction in experimental models of acute kidney ischemia-reperfusion injury. Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Kidney Transplantation
What is being tested?
Recombinant erythropoietin alpha (rHuEPO alpha)
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
88 participants
Where
1 siteGermany
Study dates
Feb 2007to Nov 2009
Phase
Phase 2/3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Signed written informed consent
  • Male or female aged 18 to 70 years without restricted legal competence and being able to follow the trial instructions
  • Cadaveric renal transplant, cold ischemia time below 24 h, and standard immunosuppressive regimen
  • A haemoglobin level > 8 and < 14 g/dl
  • Treatment with standard immunosuppression (steroids, cyclosporine A, tacrolimus, MMF or azathioprine)
  • In patient with diabetes mellitus HbA1c < 9%

Who cannot join

  • Previous or current myelodysplastic or -proliferative disorders
  • History of cancer within the last 5 years.
  • Systemic chemotherapy or radiotherapy
  • Higher degree renal anemia or persistent Hb > 14 g/dl
  • Treatment with other stem cell growth factors cells like GM-CSF, VEGF
  • Bleeding episodes within 3 month prior transplantation
Show all 19Show fewer
  • Sitting diastolic BP > 110 mmHg or sitting systolic BP > 170 mmHg
  • Known intolerance of rHuEpo or analogs
  • Cardiovascular event within 6 months prior transplantation
  • Thromboembolic event within 6 months prior transplantation
  • Relevant stenosis of extra- and intracranial, and peripheral arteries
  • Systemic diseases (SLE or vasculitis)
  • Acute or chronic infection and/or CRP > 10 mg/l prior transplantation
  • Hemolysis or disorders of blood formation (e.g., thalassemia)
  • Further organ transplants or combined organ transplantation
  • Pregnancy or inadequate contraception
  • Psychiatric or emotional problems, or chronic seizures
  • Unwillingness to participate satisfactorily for the entire trial period
  • Participation in a clinical trial within 30 days prior to study inclusion

Trial locations and contacts

1 site in 1 country.

Germany1 site
  • Hannover Medical School

    Hanover, 30625

Other trials in Germany

About this study

Official title: Effect of Erythropoietin on Renal Function After Kidney Transplantation

The hematopoetic cytokine erythropoietin (EPO) has been shown to reduce programmed cell death and tissue destruction in experimental models of acute kidney ischemia-reperfusion injury. Thus, treatment with high dose recombinant human EPO (rHuEPO) may prevent kidney tissue damage and loss of renal function after successful kidney transplantation in humans.

Read the detailed description

Erythropoietin (EPO) has pleiotropic effects well beyond the maintenance of red blood cell mass. In the embryo, EPO is a major regulator of vascular formation and organ growth, and EPO receptors are found in almost every embryonic tissue. EPO receptors also exist in many adult tissues including renal tissue, and even the notion of autocrine or paracrine EPO systems has been raised. Although the peritubular fibroblasts are the major adult site for EPO production, EPO receptors have been demonstrated in many kidney cell types, e.g. proximal tubule epithelial cells, mesangial cells, and the glomerulus. Moreover, EPO has important cytoprotective effects on various cell lines and organs, and protection from ischemic injury and inhibition of apoptotic death-related pathways has been reported in brain, heart and renal tissue. The intracellular pathways involved in these favourable EPO effects may involve nuclear translocation of the transcription factor NF- B, JAK2 phosphorylation and phosphorylation of Akt (protein kinase B).

A recent experimental study revealed that cobalt administration to rats caused up-regulation of EPO, and diminished the degree of renal injury caused by ischemia-reperfusion (I/R), suggesting that EPO may also play an important role in renal ischemic preconditioning. Indeed, subsequent studies from different laboratories demonstrated that preconditioning with recombinant human EPO (rHuEPO) is protective against I/R injury in rodents. In this respect data on specific protective effects of rHuEPO and its analogues on endothelial cells of glomeruli are of particular interest. Furthermore, administration of rHuEPO may not have only protective effects on the vascular level, but also potential of regeneration, since EPO also stimulates proliferation and differentiation of regenerative cells such as endothelial progenitor cells (EPCs).

Renal ischemia, whether caused by shock or after surgery, is a major cause of acute renal failure (ARF) in man. In this respect kidney transplantation is a classical model of ARF due to I/R injury, since the transplanted organ is connected to the recipients blood supply usually after several hours of "cold ischemia". Although reperfusion is essential for the survival of ischemic tissue, it also initiates a complex and interrelated sequence of events that results in injury and the eventual death of renal cells as a result of a combination of both apoptosis and necrosis. Apoptotic cell death has been documented in human biopsies after renal I/R, and inhibition of apoptotic signalling and cell death ameliorates the associated injury and inflammation in an experimental model of ischemic ARF. Similarly, I/R damage of transplanted kidney is thought to be a major factor limiting renal function after successful transplantation.

Being tested
Recombinant erythropoietin alpha (rHuEPO alpha), Placebo

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Recombinant erythropoietin alpha (rHuEPO alpha)Drug

    Also called Erypo

    Erythropoietin alpha 3 x 40.000 IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation

  • PlaceboDrug

    Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation

Study groups in NCT00425698
Study groupRoleWhat they receive
intravenous erythropoietinActive comparatorErythropoietin alpha 3 x 40.000 IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
Receives: Drug: Recombinant erythropoietin alpha (rHuEPO alpha); Drug: Placebo
intravenous placeboPlacebo comparatorPlacebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Kidney Graft Function by Estimated Glomerular Filtration Rate (eGFR)

    Estimated glomerular filtration rate (eGFR) was assessed using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)equation

    Measured: 42 days after transplantation

Secondary outcomes (1)
  1. Kidney Graft Function by Estimated Glomerular Filtration Rate (eGFR)

    Estimated glomerular filtration rate (eGFR) was assessed using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)equation

    Measured: 6 month after transplantation

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Jan 2007 (estimated)
  2. Study startFeb 2007
  3. Primary completionMay 2009
  4. Study completionNov 2009

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2/3
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
88 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00425698
Sponsor's protocol ID
MHH - EPONTX - 01/06
Status last verified
Sep 2010
First submitted
22 Jan 2007
Last updated
28 Sep 2010
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 2/3 study testing Recombinant erythropoietin alpha (rHuEPO alpha) in people with Kidney Transplantation, run by Hannover Medical School at 1 site in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Sep 2010. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 23 Sep 2010). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Kidney Graft Function by Estimated Glomerular Filtration Rate (eGFR) (time frame: 42 days after transplantation). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2010.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in